Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $44.3B | $12.1B | $6.5B | $7.4B | 12.5% | 5.7% | -51.3% |
| 2024 | $42.0B | $10.8B | $13.4B | $6.4B | 28.1% | 4.6% | 134.2% |
| 2023 | $40.1B | $10.5B | $5.7B | $5.1B | 14.8% | -8.1% | -17.5% |
| 2022 | $43.7B | $12.1B | $6.9B | $7.8B | 18.9% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 43,653 | 40,109 | 41,950 | 44,328 |
| Operating Revenue | - | 43,653 | 40,109 | 41,950 | 44,328 |
| Cost Of Revenue | - | 19,142 | 17,975 | 18,706 | 19,319 |
| Gross Profit | - | 24,511 | 22,134 | 23,244 | 25,009 |
| Operating Expense | - | 16,149 | 15,656 | 16,419 | 16,956 |
| Research And Development | - | 2,888 | 2,741 | 2,844 | 2,942 |
| Selling General And Administration | - | 11,248 | 10,949 | 11,697 | 12,332 |
| Total Expenses | - | 35,291 | 33,631 | 35,125 | 36,275 |
| Operating Income | - | 8,362 | 6,478 | 6,825 | 8,053 |
| Total Operating Income As Reported | - | 8,362 | 6,478 | 6,825 | 8,053 |
| EBITDA | - | 12,131 | 10,544 | 10,790 | 12,075 |
| Normalized EBITDA | - | 12,133 | 10,585 | 10,763 | 12,025 |
| EBIT | - | 8,864 | 7,301 | 7,572 | 8,959 |
| Interest Income | - | 183 | 385 | 344 | 308 |
| Interest Expense | - | 558 | 637 | 559 | 493 |
| Net Interest Income | - | -375 | -252 | -215 | -185 |
| Other Non Operating Income Expenses | - | 321 | 479 | 376 | 548 |
| Other Income Expense | - | 319 | 438 | 403 | 598 |
| Interest Income Non Operating | - | 183 | 385 | 344 | 308 |
| Interest Expense Non Operating | - | 558 | 637 | 559 | 493 |
| Net Non Operating Interest Income Expense | - | -375 | -252 | -215 | -185 |
| Pretax Income | - | 8,306 | 6,664 | 7,013 | 8,466 |
| Tax Provision | - | 1,373 | 941 | -6,389 | 1,942 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.33 | -5.78 | 5.67 | 11.45 |
| Net Income Continuous Operations | - | 6,933 | 5,723 | 13,402 | 6,524 |
| Net Income From Continuing And Discontinued Operation | - | 6,933 | 5,723 | 13,402 | 6,524 |
| Net Income From Continuing Operation Net Minority Interest | - | 6,933 | 5,723 | 13,402 | 6,524 |
| Net Income | - | 6,933 | 5,723 | 13,402 | 6,524 |
| Net Income Common Stockholders | - | 6,933 | 5,723 | 13,402 | 6,524 |
| Net Income Including Noncontrolling Interests | - | 6,933 | 5,723 | 13,402 | 6,524 |
| Normalized Income | - | 6,934.67 | 5,758.22 | 13,380.67 | 6,485.45 |
| Diluted NI Availto Com Stockholders | - | 6,933 | 5,723 | 13,402 | 6,524 |
| Basic Average Shares | - | 1,737.80 | 1,734.08 | 1,731.70 | 1,736.60 |
| Diluted Average Shares | - | 1,764 | 1,749 | 1,748 | 1,749 |
| Reconciled Depreciation | - | 3,267 | 3,243 | 3,218 | 3,116 |
| Reconciled Cost Of Revenue | - | 17,888 | 16,698 | 17,366 | 17,885 |
| Total Unusual Items | - | -2 | -41 | 27 | 50 |
| Total Unusual Items Excluding Goodwill | - | -2 | -41 | 27 | 50 |
| Net Income Discontinuous Operations | 0 | 0 | - | - | - |
| Special Income Charges | 0 | - | - | - | - |
| Gain On Sale Of Security | - | -2 | -41 | 27 | 50 |
| Depreciation Amortization Depletion Income Statement | - | 2,013 | 1,966 | 1,878 | 1,682 |
| Depreciation And Amortization In Income Statement | - | 2,013 | 1,966 | 1,878 | 1,682 |
| Amortization | - | 2,013 | 1,966 | 1,878 | 1,682 |
| Amortization Of Intangibles Income Statement | - | 2,013 | 1,966 | 1,878 | 1,682 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Abbott Laboratoriesthis co. | ABT | $158.1B | 24.24 | 3.03 | 12.5% | 13.54 |
| Amgen Inc. | AMGN | $186.5B | 24.19 | 21.54 | 89.1% | 13.73 |
| Thermo Fisher Scientific Inc. | TMO | $179.1B | 26.72 | 3.35 | 12.6% | 18.11 |
| Gilead Sciences, Inc. | GILD | $160.4B | 18.85 | 7.06 | 37.5% | 12.94 |
| Intuitive Surgical, Inc. | ISRG | $148.3B | 51.94 |
| - |
| - |
| - |
| - |
| - |
| 8.32 |
| 16.0% |
| 39.33 |
| Pfizer Inc. | PFE | $146.4B | 18.84 | 1.69 | 9.0% | 12.47 |
| Danaher Corporation | DHR | $132.1B | 36.55 | 2.51 | 6.9% | 21.19 |
| CVS Health Corporation | CVS | $121.0B | 68.43 | 1.61 | 2.4% | 19.52 |
| Bristol-Myers Squibb Company | BMY | $115.6B | 16.39 | 6.26 | 38.2% | 10.01 |
| Peer Median | - | 25.45 | 4.81 | 14.3% | 15.92 | |